Pembrolizumab companion diagnostic - Dako/Merck

Drug Profile

Pembrolizumab companion diagnostic - Dako/Merck

Alternative Names: Lambrolizumab companion diagnostic - Dako/Merck; PD-L1 IHC 22C3 pharmDx

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dako A/S; Merck & Co
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Gastric cancer; Non-small cell lung cancer

Most Recent Events

  • 25 Sep 2017 Launched for Gastric cancer (Diagnosis) in USA (unspecified route)
  • 22 Sep 2017 Registered for Gastric cancer (Diagnosis) in USA (unspecified route)
  • 24 Oct 2016 US FDA approves sNDA for pembrolizumab companion diagnostic for Non-small cell lung cancer (Diagnosis, in patients with PD-L1 tumour proportion score of 1% or more)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top